Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Cancer Type:
Liver cancer, adult primary
Trial Type:
Treatment
Treatment/Intervention:
antiangiogenesis therapy
Trial Status:
Active
Trial Phase:
Phase III
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
RFA005
, NCT00728078
2.
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
20 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
T2202
, NCT00225290
3.
Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
SiLVER05
, EudraCT Number:, 2005-005362-36, NCT00355862
4.
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular CarcinoMa (STORM)
Phase:
Phase III
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
12414
, 2008-001087-36, STORM, NCT00692770
5.
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A6181170
, NCT00699374
6.
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CA182-034
, EUDRACT #: 2008-005084-34, NCT00825955
7.
First Line Hepato Cellular Carcinoma (HCC)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CA182-033
, EUDRACT # 2008-003533-24, NCT00858871
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute